The Center for Biosimilars recaps the top 5 biosimilars articles for the week of March 5, 2018.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 5.
Number 5: Michigan has become the latest state to enact legislation governing the pharmacy-level substitution of interchangeable biosimilars.
Number 4: Dr Gillian Woollett, of Avalere Health, told The Center for Biosimilars® that the United States does not have to reinvent the wheel on biosimilar safety, but can learn from international experience.
Number 3: A systematic literature review shows that switching to a biosimilar carries only a low risk of safety concerns or loss of efficacy.
Number 2: Samsung Bioepis’ Ontruzant launched in the United Kingdom this week as the first biosimilar trastuzumab to enter the European market.
Number 1: Dr Scott Gottlieb, Commissioner of the FDA, said in remarks delivered at the National Health Policy Conference of America’s Health Insurance Plans that the economics of biosimilar development in the United States are "currently unstable."
Finally, last week, our e-newsletter asked for your thoughts on whether the FDA should levy fines against research entities that fail to disclose their clinical trial data.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.